Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

68 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Targeting ITGB4/SOX2-driven lung cancer stem cells using proteasome inhibitors.
Guo L, Mohanty A, Singhal S, Srivastava S, Nam A, Warden C, Ramisetty S, Yuan YC, Cho H, Wu X, Li A, Vohra M, Saladi SV, Wheeler D, Arvanitis L, Massarelli E, Kulkarni P, Zeng Y, Salgia R. Guo L, et al. Among authors: arvanitis l. iScience. 2023 Jul 10;26(8):107302. doi: 10.1016/j.isci.2023.107302. eCollection 2023 Aug 18. iScience. 2023. PMID: 37554452 Free PMC article.
Acquired resistance to KRAS G12C small-molecule inhibitors via genetic/nongenetic mechanisms in lung cancer.
Mohanty A, Nam A, Srivastava S, Jones J, Lomenick B, Singhal SS, Guo L, Cho H, Li A, Behal A, Mirzapoiazova T, Massarelli E, Koczywas M, Arvanitis LD, Walser T, Villaflor V, Hamilton S, Mambetsariev I, Sattler M, Nasser MW, Jain M, Batra SK, Soldi R, Sharma S, Fakih M, Mohanty SK, Mainan A, Wu X, Chen Y, He Y, Chou TF, Roy S, Orban J, Kulkarni P, Salgia R. Mohanty A, et al. Among authors: arvanitis ld. Sci Adv. 2023 Oct 13;9(41):eade3816. doi: 10.1126/sciadv.ade3816. Epub 2023 Oct 13. Sci Adv. 2023. PMID: 37831779 Free PMC article.
Expansion of endogenous T cells in CSF of pediatric CNS tumor patients undergoing locoregional delivery of IL13R〿2-targeting CAR T cells: an interim analysis.
Wang L, Oill AT, Blanchard M, Wu M, Hibbard J, Sepulveda S, Peter L, Kilpatrick J, Munoz M, Stiller T, Shulkin N, Wagner J, Dolatabadi A, Nisis M, Shepphird J, Sanchez G, Lingaraju C, Manchanda M, Natri H, Kouakanou L, Sun G, Oliver-Cervantes C, Georges J, Aftabizadeh M, Forman S, Priceman S, Ressler J, Arvanitis L, Cotter J, D'Apuzzo M, Tamrazi B, Badie B, Davidson T, Banovich N, Brown C. Wang L, et al. Among authors: arvanitis l. Res Sq [Preprint]. 2023 Oct 23:rs.3.rs-3454977. doi: 10.21203/rs.3.rs-3454977/v1. Res Sq. 2023. PMID: 37961215 Free PMC article. Preprint.
Predicting survival of NSCLC patients treated with immune checkpoint inhibitors: Impact and timing of immune-related adverse events and prior tyrosine kinase inhibitor therapy.
Sayer MR, Mambetsariev I, Lu KH, Wong CW, Duche A, Beuttler R, Fricke J, Pharoan R, Arvanitis L, Eftekhari Z, Amini A, Koczywas M, Massarelli E, Roosan MR, Salgia R. Sayer MR, et al. Among authors: arvanitis l. Front Oncol. 2023 Feb 13;13:1064169. doi: 10.3389/fonc.2023.1064169. eCollection 2023. Front Oncol. 2023. PMID: 36860308 Free PMC article.
Clinical and Molecular Features of KRAS-Mutated Lung Cancer Patients Treated with Immune Checkpoint Inhibitors.
Zhao D, Li H, Mambetsariev I, Mirzapoiazova T, Chen C, Fricke J, Kulkarni P, Villaflor V, Arvanitis L, Hamilton S, Afkhami M, Pillai R, Armstrong B, Erhunmwunsee L, Massarelli E, Sattler M, Amini A, Salgia R. Zhao D, et al. Among authors: arvanitis l. Cancers (Basel). 2022 Oct 8;14(19):4933. doi: 10.3390/cancers14194933. Cancers (Basel). 2022. PMID: 36230855 Free PMC article.
68 results